|
| ‧ 專利名稱 |
去整合蛋白變異體及其醫藥用途(DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF) |
| ‧ 專利證書號 |
-
CN101677537B
JP05908666B2
HK1136160B
SG201400709B
EP2124548B1
AU2007343734B2
|
| ‧ 專利權人 |
台大(50％)、成大(50％) |
‧ 專利國家
(申請日) |
PCT (2007/12/21)
中國 (2007/12/21)
歐洲 (2007/12/21)
加拿大 (2009/06/09)
巴西 (2009/06/25)
日本 (2009/06/25)
以色列 (2009/06/25)
墨西哥 (2009/06/26)
澳洲 (2009/06/26)
印度 (2009/07/07)
俄羅斯 (2009/07/24)
韓國 (2009/07/24)
香港 (2010/03/30)
新加坡 (2012/08/03)
|
| ‧ 發明人 |
莊偉哲, 符文美, 黃德富, 黃溫雅, 湯智昕, 陳秋月, |
|
|
 技術摘要： |
Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and/or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin αllbβ3 and/or α5β1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of αvβ3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.
|
聯繫方式 |
| 聯絡人：
研發處產學合作總中心 |
電話：
(02)3366-9949 |
|
| 地 址：
10617臺北市大安區羅斯福路四段1號 禮賢樓六樓608室 |
|
|
| |
|
專利行銷平台